Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic

被引：0
|
作者：
Liegeon, Geoffroy [1 ]
Kaperak, Christopher [1 ]
Friedman, Eleanor E. [1 ]
Djuricich, Paul [2 ]
Dawdani, Alicia [1 ]
Stafford, Kane [2 ]
Plotkin, Sophie [1 ]
Schmitt, Jessica [1 ]
Hazra, Aniruddha [1 ]
Christopoulos, Katerina A. [3 ]
Schneider, John A. [1 ]
Mcnulty, Moira C. [1 ]
机构：
[1] Univ Chicago, Dept Med, Chicago, IL USA
[2] Univ Chicago, Dept Pharm, Chicago, IL USA
[3] Univ Calif San Francisco, Div HIV ID & Global Med, San Francisco, CA USA
来源：
OPEN FORUM INFECTIOUS DISEASES | 2025年 / 12卷 / 03期
基金：
美国国家卫生研究院;
关键词：
cabotegravir; injectable; long-acting; people with HIV; rilpivirine; PROGRAM; CARE;
D O I：
10.1093/ofid/ofaf094
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We describe referrals and uptake of long-acting injectable cabotegravir/rilpivirine at an academic clinic in Chicago. In a pharmacy-led model, 118 (18%) people with HIV were referred and 78 (12%) initiated long-acting injectable cabotegravir/rilpivirine from 1 January 2021 to 31 May 2023. Implementation, especially for people with HIV who were not virally suppressed, requires further support for patients, providers, and clinic systems.
引用
收藏
页数：7
相关论文
共 50 条
  • [1] Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV
    van der Wekken-Pas, Lena
    Weiss, Fabian
    Simon-Zuber, Charlotte
    Sebisch, Rena
    Wiese, Carmen
    van Leeuwen, Elisabeth
    Burger, David
    Colbers, Angela
    CLINICAL INFECTIOUS DISEASES, 2024, 79 (06) : 1468 - 1471
  • [2] Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic
    Howe, Zach W.
    Norman, Sarah
    Lueken, Abbie F.
    Huesgen, Emily
    Farmer, Eric K.
    Jarrell, Kaitlyn
    Mathis, Joscelyn E.
    Bonham, Kyle W.
    Hahn, Julie
    PHARMACOTHERAPY, 2021, 41 (08): : 686 - 699
  • [3] Use of long-acting injectable cabotegravir/rilpivirine in people with HIV and adherence challenges
    Christopoulos, Katerina A.
    Hickey, Matthew D.
    Rana, Aadia
    CURRENT OPINION IN HIV AND AIDS, 2025, 20 (01) : 11 - 18
  • [4] Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South
    Collins, Lauren F.
    Corbin-Johnson, Della
    Asrat, Meron
    Morton, Zoey P.
    Dance, Kaylin
    Condra, Alton
    Jenkins, Kimberly
    Todd-Turner, Marie
    Sumitani, Jeri
    Smith, Bradley L.
    Armstrong, Wendy S.
    Colasanti, Jonathan A.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (09):
  • [5] Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine
    Hill, Lucas A.
    Abulhosn, Kari K.
    Yin, Jeffrey F.
    Bamford, Laura P.
    AIDS, 2023, 37 (04) : 605 - 609
  • [6] Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine
    Alagaratnam, Jasmini
    Kelly, Niall
    Dustan, Simon
    Naous, Nadia
    Nwanbila, Modest
    Byrne, Ruth
    Girometti, Nicolo
    Asboe, David
    Taylor, Graham P.
    Boffito, Marta
    AIDS, 2025, 39 (01) : 95 - 98
  • [7] Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection
    Zeuli, John D.
    Rivera, Christina G.
    Smith, Bradley L.
    Otto, Ashley
    Temesgen, Zelalem
    DRUGS OF TODAY, 2022, 58 (12) : 555 - 576
  • [8] Early adopters of long-acting injectable cabotegravir/rilpivirine: what lessons can we learn?
    Wood, Brian R.
    Kumarasamy, Nagalingeswaran
    AIDS, 2024, 38 (03) : 425 - 426
  • [9] Long-Acting Injectable Cabotegravir plus Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
    Rizzardini, Giuliano
    Overton, Edgar T.
    Orkin, Chloe
    Swindells, Susan
    Arasteh, Keikawus
    Gorgolas Hernandez-Mora, Miguel
    Pokrovsky, Vadim
    Girard, Pierre-Marie
    Oka, Shinichi
    Andrade-Villanueva, Jaime F.
    Richmond, Gary J.
    Baumgarten, Axel
    Masia, Mar
    Latiff, Gulam
    Griffith, Sandy
    Harrington, Conn M.
    Hudson, Krischan J.
    St Clair, Marty
    Talarico, Christine L.
    Patel, Parul
    Cutrell, Amy
    Van Eygen, Veerle
    D'Amico, Ronald
    Mrus, Joseph M.
    Wu, Sterling
    Ford, Susan L.
    Chow, Ken
    Roberts, Jeremy
    Wills, Angela
    Walters, Nicola
    Vanveggel, Simon
    Van Solingen-Ristea, Rodica
    Crauwels, Herta
    Smith, Kimberly Y.
    Spreen, William R.
    Margolis, David A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (04) : 498 - 506
  • [10] Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis
    van Welzen, Berend J.
    Van Lelyveld, Steven F. L.
    Ter Beest, Gerjanne
    Gisolf, Jet H.
    Geerlings, Suzanne E.
    Prins, Jan M.
    Van Twillert, Gitte
    Van Nieuwkoop, Cees
    Van der Valk, Marc
    Burger, David
    Wensing, Annemarie M. J.
    CLINICAL INFECTIOUS DISEASES, 2024, 79 (01) : 189 - 195
12345